EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning

Jan Stourac, Simeon Borko iD, Rayyan T Khan, Petra Pokorna, Adam Dobias, Joan Planas-Iglesias iD, Stanislav Mazurenko iD, Gaspar Pinto, Veronika Szotkowska, Jaroslav Sterba, Ondrej Slaby, Jiri Damborsky und 1 weitere

Briefings in Bioinformatics · 2023

DOI: 10.1093/bib/bbad441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2023. Verfasst von Jan Stourac und 12 weiteren Autor:innen. Beteiligte Einrichtung: Loschmidt Laboratories, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Precision Medicine, Melanoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Ministry of Education, Technology Agency of the Czech Republic, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PredictONCO 1.0 is a unique web server that analyzes effects of mutations on proteins frequently altered in various cancer types. The server can assess the impact of mutations on the protein sequential and structural properties and apply a virtual screening to identify potential inhibitors that could be used as a highly individualized therapeutic approach, possibly based on the drug repurposing. PredictONCO integrates predictive algorithms and state-of-the-art computational tools combined with information from established databases. The user interface was carefully designed for the target specialists in precision oncology, molecular pathology, clinical genetics and clinical sciences. The tool summarizes the effect of the mutation on protein stability and function and currently covers 44 common oncological targets. The binding affinities of Food and Drug Administration/ European Medicines Agency -approved drugs with the wild-type and mutant proteins are calculated to facilitate treatment decisions. The reliability of predictions was confirmed against 108 clinically validated mutations. The server provides a fast and compact output, ideal for the often time-sensitive decision-making process in oncology. Three use cases of missense mutations, (i) K22A in cyclin-dependent kinase 4 identified in melanoma, (ii) E1197K mutation in anaplastic lymphoma kinase 4 identified in lung carcinoma and (iii) V765A mutation in epidermal growth factor receptor in a patient with congenital mismatch repair deficiency highlight how the tool can increase levels of confidence regarding the pathogenicity of the variants and identify the most effective inhibitors. The server is available at https://loschmidt.chemi.muni.cz/predictonco.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineMelanomaHumansReproducibility of ResultsComputational BiologyMutationProteinsMachine Learning

Stichwörter der Autor:innen

canceroncologypersonalized medicinesingle-nucleotide polymorphismtargeted therapy

Substanzen

Proteins

Autor:innen und Institutionen

  • Loschmidt Laboratories, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Loschmidt Laboratories, RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
  • IT4Innovations Centre of Excellence, Faculty of Information Technology, Brno University of Technology, Brno, Czech Republic.
  • Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

ORCID-Profile: Simeon Borko, Joan Planas-Iglesias, Stanislav Mazurenko, David Bednar

Förderung

  • Czech Ministry of Education
  • Technology Agency of the Czech Republic
  • European Union
  • Brno University of Technology
  • Czech Ministry of Health
  • National Institute for Cancer Research

Zitieren

APA

Stourac, J., Borko, S., Khan, R. T., Pokorna, P., Dobias, A., Planas-Iglesias, J., Mazurenko, S., Pinto, G., Szotkowska, V., Sterba, J., Slaby, O., Damborsky, J., & Bednar, D. (2023). PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbad441

Vancouver

Stourac J, Borko S, Khan RT, Pokorna P, Dobias A, Planas-Iglesias J, et al. PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning. Briefings in Bioinformatics. 2023. doi:10.1093/bib/bbad441

BibTeX
@article{Stourac2023,
  author = {Stourac, Jan and Borko, Simeon and Khan, Rayyan T and Pokorna, Petra and Dobias, Adam and Planas-Iglesias, Joan and Mazurenko, Stanislav and Pinto, Gaspar and Szotkowska, Veronika and Sterba, Jaroslav and Slaby, Ondrej and Damborsky, Jiri and Bednar, David},
  title = {PredictONCO: a web tool supporting decision-making in precision oncology by extending the bioinformatics predictions with advanced computing and machine learning},
  journal = {Briefings in Bioinformatics},
  year = {2023},
  doi = {10.1093/bib/bbad441}
}
Kostenlos starten →